Fig. 6
From: CERTL reduces C16 ceramide, amyloid-β levels, and inflammation in a model of Alzheimer’s disease
Neuronal increase of CERTL reduces Aβ by decreasing APP cleavage. a Representative photomicrographs of sagittal brain sections imaging the motor sensory cortex (M1 and M2) stained for nuclei in blue and Aβ plaques in green. All photomicrographs were exposed and processed identically. Scale bar represents 200 and 50 μm (from right to left). b Immunofluorescent quantification of plaques measured by the percentage of area, plaques counts/mm2. c Frequency distribution of plaques based on size (10–25 μm) (error bars represent ± SEM of 4–6 animals per experimental condition, ANOVA, Bonferroni correction, significant effects, *p < 0.05; **p < 0.01). d Aβ quantification in three extraction buffers, BS, TBS-T, and formic acid (FA) by ELISA showed that Aβ was significantly reduced in the soluble fractions in the cortex but not in the insoluble fraction (Student’s t test *p < 0.05). e Western blot analysis of TBS cortex homogenate stained with 6E10 antibody showed that ratios of amyloid Aβ/FL-APP and Aβ/CTFβ are reduced while CTFβ/FL-APP is increased in AAV-CERTL-treated animals while CTFβ/FL-APP is increased. Error bars represent ± SEM of 5 animals per experimental condition (Student’s t test *p < 0.05; **p < 0.01) (full length amyloid precursor protein = FL-APP; amyloid-β peptide = Aβ; C-terminal fragment β = CFTβ). Western blot membranes are shown in Supplementary Figure 5